- Home
- MIST vs INM Comparison
MIST vs INM Comparison
Compare MIST & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | INM |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | Canada | Canada |
| Employees | 38 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 7.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIST | INM |
|---|---|---|
| Price | $1.05 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 151.3K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $1.00 | $0.58 |
| 52 Week High | $3.06 | $2.50 |
Technical Indicators
Market Signals| Indicator | MIST | INM |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 48.71 |
| Support Level | $1.01 | $1.42 |
| Resistance Level | $1.42 | $1.52 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 9.26 | 48.33 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.